Literature DB >> 17848659

Cardiovascular risk and the thiazolidinediones: déjà vu all over again?

Daniel H Solomon, Wolfgang C Winkelmayer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17848659     DOI： 10.1001/jama.298.10.1216

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

Review 1.  Pharmacovigilance: methods, recent developments and future perspectives.

Authors:  L Härmark; A C van Grootheest
Journal:  Eur J Clin Pharmacol       Date:  2008-06-04       Impact factor: 2.953

2.  Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.

Authors:  Angel Rodríguez; Jesús Reviriego; Vasilios Karamanos; Francisco J del Cañizo; Nikolaos Vlachogiannis; Vangelis Drossinos
Journal:  Cardiovasc Diabetol       Date:  2011-02-11       Impact factor: 9.951

3.  Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.

Authors:  David N Juurlink; Tara Gomes; Lorraine L Lipscombe; Peter C Austin; Janet E Hux; Muhammad M Mamdani
Journal:  BMJ       Date:  2009-08-18

Review 4.  Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.

Authors:  Bernd Richter; Elizabeth Bandeira-Echtler; Karla Bergerhoff; Christian Lerch
Journal:  Vasc Health Risk Manag       Date:  2008
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.